Cargando…
Updated Immunotherapy for Gastric Cancer
Gastric cancer treatments are evolving rapidly. For example, immune checkpoint inhibitors, especially those that target PD-1 or PD-L1, have long-term efficacy in a subset of gastric cancer patients, and are currently the first-line therapy. Immunotherapies approved for use in untreated gastric cance...
Autores principales: | Narita, Yukiya, Muro, Kei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10094960/ https://www.ncbi.nlm.nih.gov/pubmed/37048719 http://dx.doi.org/10.3390/jcm12072636 |
Ejemplares similares
-
Dramatic Response in a Patient with Metastatic Gastric Cancer Using Trifluridine/Tipiracil after Rapid Disease Progression while on Nivolumab
por: Nozawa, Kazuki, et al.
Publicado: (2020) -
Marked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability‐high gastric cancer with insufficient oral intake
por: Ogata, Takatsugu, et al.
Publicado: (2020) -
Breast Cancer Immunotherapy: An Update
por: Makhoul, Issam, et al.
Publicado: (2018) -
Recent updates on cancer immunotherapy
por: Liu, Ming, et al.
Publicado: (2018) -
Immunotherapy in Gastric Cancer
por: Högner, Anica, et al.
Publicado: (2022)